United States
Germany
Japan
United Kingdom
China
PRMT2 (NM_206962) Human Tagged ORF Clone Lentiviral Particle
CAT＃: RC200461L2V
- LentiORF®
-
Lenti ORF particles, PRMT2 (mGFP-tagged) - Human protein arginine methyltransferase 2 (PRMT2), transcript variant 1, 200ul, >10^7 TU/mL
Need custom lentivirus service?
Get a free quote
CNY 9,975.00
Product images
CNY 1,999.00
CNY 2,700.00
Specifications
| Product Data | |
| Product Name | PRMT2 (NM_206962) Human Tagged ORF Clone Lentiviral Particle |
| Synonyms | HRMT1L1 |
| Vector | pLenti-C-mGFP |
| ACCN | NM_206962 |
| ORF Size | 1299 bp |
| Sequence Data |
The ORF insert of this clone is exactly the same as(RC200461).
|
| OTI Disclaimer | The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This clone is substantially in agreement with the reference, but a complete review of all prevailing variants is recommended prior to use. More info |
| OTI Annotation | This clone was engineered to express the complete ORF with an expression tag. Expression varies depending on the nature of the gene. |
| Reference Data | |
| RefSeq | NM_206962.1 |
| RefSeq Size | 2446 bp |
| RefSeq ORF | 1302 bp |
| Locus ID | 3275 |
| Protein Families | Druggable Genome |
| MW | 49 kDa |
| Gene Summary | Arginine methyltransferase that methylates the guanidino nitrogens of arginyl residues in proteins such as STAT3, FBL, histone H4. Acts as a coactivator (with NCOA2) of the androgen receptor (AR)-mediated transactivation. Acts as a coactivator (with estrogen) of estrogen receptor (ER)-mediated transactivation. Enhances PGR, PPARG, RARA-mediated transactivation. May inhibit NF-kappa-B transcription and promote apoptosis. Represses E2F1 transcriptional activity (in a RB1-dependent manner). May be involved in growth regulation.[UniProtKB/Swiss-Prot Function] |
Documents
| Product Manuals |
| FAQs |
| SDS |
